SynthesisBipolar disorders2026
Bipolar Disorder and Perimenopause: An Update.
Synthesis in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesPerimenopause has been associated with mood worsening in some individuals, including increased depressive symptoms. Yet, the link between bipolar disorder (BD) and perimenopause remains understudied. This review aimed to provide an update on recent original studies and contextualize findings within the broader literature to guide future research and clinical practice.
methodsA systematic search was conducted on Embase (January 1, 2018 to August 5, 2026) to identify studies on BD (I, II, or NOS/BD spectrum) that directly or indirectly examined perimenopause and BD. Pooled samples were included if they reported separate BD results. Results were narratively synthesized.
resultsFourteen studies were identified from Australia (n = 4), Italy (n = 3), UK (n = 2), Taiwan (n = 1), South Korea (n = 1), Sweden (n = 1), USA (n = 1), and one study of international trials. There is converging evidence showing that perimenopause is a period of higher risk of first onset BD. Among individuals with existing BD, increased depression and heightened anxiety during perimenopause were the most consistent illness-course findings, whereas findings for hypo/mania were mixed. Evidence concerning psychotherapy or pharmacological treatment, including hormone replacement therapy, was limited or absent.
conclusionsThis review provides an updated perspective on BD and perimenopause, extending existing knowledge beyond mood symptoms and identifying several clinical and research gaps. Clinicians should consider the potential impact of perimenopause in BD management. Research using standardized menopause staging criteria (e.g., STRAW+10) is encouraged to inform mechanisms, illness trajectories, treatments, and to better support individuals with BD through perimenopause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.